Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cell Conditioned Medium for Post COVID-19 Condition
jRCT1051260128Recruiting
- Sponsor
- Heiwa Clinic
- Start
- Apr 2024
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in post-COVID syndrome, sponsored by Heiwa Clinic. Primary endpoint: Change in post COVID-19 condition status at 1 month. Started Apr 2024; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on jRCT1051260128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051260128.